NanoViricides, Inc. Reports Oral FluCide™ is Highly Effective Against H3N2 Influenza A Virus and Superior to Tamiflu® Based on Increased Survival in a Lethal Influenza Animal Model

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTCBB: NNVC) (the "Company") reported today that its oral FluCide™ drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus. Animals treated with the oral anti-influenza nanoviricide drug candidates survived for much longer as compared to Tamiflu® treated animals.